Hosted on MSN8m
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Full Year 2024 Results Key Financial Results Revenue: US$45.0b (up 32% from FY 2023).
In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback